Press Releases

GlobeNewswire, Inc.

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher...

GlobeNewswire, Inc.

Completed separation from The Middleby Corporation on July 6, 2026 Strong demand with orders up 16% year-over-year Raises Full-Year 2026 Guidance ROSEMONT, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Midera Food Processing, Inc. (Nasdaq: MFP)...

EIN Presswire

The Business Research Company’s Library Preparation (Prep) System Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, August 13, 2026 /⁨EINPresswire.com⁩/ -- The library preparation...

GlobeNewswire, Inc.

Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are...

EIN Presswire

Next-generation operational intelligence empowers Castelo Cold Storage to deliver real-time quality assurance, zero-friction compliance, and unique value AUSTIN, TX, TX, UNITED STATES, August 13, 2026 /⁨EINPresswire.com⁩/ -- ProduceX, an AI...

GlobeNewswire, Inc.

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL...

GlobeNewswire, Inc.

PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today...

GlobeNewswire, Inc.

Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY...

GlobeNewswire, Inc.

Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with...

GlobeNewswire, Inc.

Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage declined 19% sequentially...

GlobeNewswire, Inc.

Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025 Q2 2026 fully diluted GAAP EPS of $0.35, non-GAAP fully diluted EPS of $0.43; EBITDA of $14.1 million, Adjusted EBITDA of $16.2 million Raising full...

GlobeNewswire, Inc.

Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026...

GlobeNewswire, Inc.

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE...

GlobeNewswire, Inc.

REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 NCCN® Clinical Practice...

GlobeNewswire, Inc.

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS, highlighting long-term...

GlobeNewswire, Inc.

Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H...

EIN Presswire

Free guidance from Cape Town's LekkerOnline shows SA guesthouse owners how phone photos, honest rates and one weekend of work win more direct bookings.

GlobeNewswire, Inc.

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients...

GlobeNewswire, Inc.

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the...

EIN Presswire

The U.S. CHIPS and Science Act has committed USD 52.7 billion to domestic semiconductor manufacturing NEW YORK, NY, UNITED STATES, August 20, 2026 /⁨EINPresswire.com⁩/ -- The Air Purifier Market reached USD 17.22 billion in 2025 and is projected...